ExoCoBio Inc., based in South Korea, has reported publishing a scientific paper indicating that stem cell-derived exosomes dramatically relieve atopic dermatitis and inhibit a variety of inflammatory targets in Stem Cell Research and Therapy. The open-access article, published online on July 11, 2018, is titled “Exosomes Derived from Human Adipose Tissue-Derived Mesenchymal Stem Cells Alleviate Atopic Dermatitis.” According to the paper, the symptoms of mice having severe atopic dermatitis were significantly improved after administration of stem cell-derived exosomes intravenously or subcutaneously, so that the level of serum immunoglobulin E (IgE), the number of eosinophils in blood, and the number of mast cells in the skin lesion were decreased. It has also been found that the number of inflammatory dendritic epidermal cells (IDECs), which are not found in normal skin but cause an allergic inflammatory response in atopic dermatitis lesions, also significantly decreased to a normal skin level after administration of stem cell-derived exosomes. In addition, the improvement of the symptoms by stem cell-derived exosomes was comparable to that of a steroid drug, prednisolone. While atopic dermatitis is a chronic disease depreciating the quality of life, there is no fundamental treatment to treat it yet. Currently available atopic treatments, such as anti-histamines, steroids, and immunosuppressive drugs, have various side effects such as impaired immune systems, liver & kidney damage during long-term administration, etc. Inhibitory antibodies against various inflammatory cytokines such as IL-4, IL-31, TNF-alpha and IL-23 are under development or on the market to relieve atopic dermatitis symptoms. However, these treatments just relieve atopic dermatitis by blocking the function of one or two specific proteins.
Login Or Register To Read Full Story